Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IRN001
MIFTS: 58

Iron Deficiency Anemia

Categories: Blood diseases, Immune diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Iron Deficiency Anemia

About this section

MalaCards integrated aliases for Iron Deficiency Anemia:

Name: Iron Deficiency Anemia 12 29 54 6 15 71
Iron-Deficiency Anemia 62

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11758
ICD9CM 34 280.8
SNOMED-CT 67 191129007
ICD10 32 D50 D50.9
UMLS 71 C0029810 C0162316
Sources

Summaries for Iron Deficiency Anemia

About this section
PubMed Health : 62 About iron-deficiency anemia: Iron-deficiency anemia is a common, easily treated condition that occurs if you don't have enough iron in your body. Low iron levels usually are due to blood loss, poor diet, or an inability to absorb enough iron from food.

MalaCards based summary : Iron Deficiency Anemia, also known as iron-deficiency anemia, is related to iron-refractory iron deficiency anemia and celiac disease 1. An important gene associated with Iron Deficiency Anemia is TMPRSS6 (Transmembrane Serine Protease 6), and among its related pathways/superpathways are Insulin receptor recycling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Clarithromycin and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone marrow and colon, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A nutritional deficiency disease that is characterized by pallor, fatigue, lightheadedness, and weakness and has material basis in low total body iron causing impaired synthesis of red blood cells.

Wikipedia : 74 Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as a decrease in the number... more...

Sources

Related Diseases for Iron Deficiency Anemia

About this section

Diseases related to Iron Deficiency Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 iron-refractory iron deficiency anemia 33.6 TMPRSS6 HJV EPO
2 celiac disease 1 31.4 TNF TFRC IL6 HFE CRP
3 thrombocytosis 31.4 THPO IL6 EPO CRP
4 hypochromic microcytic anemia 31.3 TMPRSS6 TFRC TF SLC11A2 HJV HAMP
5 hyperferritinemia with or without cataract 31.2 TFR2 TF SLC40A1 SLC11A2 HJV HFE
6 polycythemia 31.0 THPO TFRC HAMP EPO
7 hemolytic anemia 30.9 TNF TFRC TF G6PD EPO
8 congestive heart failure 30.9 TNF IL6 EPO CRP
9 sickle cell disease 30.8 TFRC G6PD EPO
10 restless legs syndrome 30.8 TFRC SLC11A2 HAMP FTL EPO
11 crohn's disease 30.8 TNF LTF IL6 CRP
12 chronic kidney disease 30.8 TNF TF IL6 HAMP FGF23 EPO
13 kidney disease 30.8 TNF TF IL6 FGF23 EPO CRP
14 thrombocytopenia 30.7 TNF THPO TFRC IL6 EPO CRP
15 rare hereditary hemochromatosis 30.7 TFR2 TF SLC40A1 HJV HFE HAMP
16 pouchitis 30.6 TNF LTF
17 purpura 30.6 TNF THPO IL6 CRP
18 iron metabolism disease 30.6 TMPRSS6 TFRC TFR2 TF SLC40A1 SLC11A2
19 urticaria 30.6 TNF IL6 CRP
20 hemosiderosis 30.6 TFR2 TF SLC40A1 SLC11A2 HJV HFE
21 alpha-thalassemia 30.5 TNF TFRC HFE HAMP G6PD EPO
22 vasculitis 30.5 TNF LTF IL6 CRP
23 sickle cell anemia 30.5 TNF IL6 G6PD EPO CRP
24 exanthem 30.5 TNF IL6 CRP
25 disease by infectious agent 30.5 TNF TFRC IL6 CRP
26 gastroenteritis 30.5 TNF IL6 CRP
27 thyroiditis 30.5 TNF IL6 CRP
28 microcytic anemia 30.4 TMPRSS6 TFRC TFR2 TF SLC40A1 SLC11A2
29 acute cystitis 30.4 TNF IL6 CRP
30 intermediate coronary syndrome 30.4 MB IL6 CRP
31 hemoglobinuria 30.4 THPO MB G6PD EPO
32 anemia of prematurity 30.4 HAMP EPO
33 haemophilus influenzae 30.4 TNF TF LTF
34 mental depression 30.4 TNF IL6 CRP
35 hemoglobinopathy 30.4 TFRC TFR2 TF MB HJV HFE
36 sideroblastic anemia 30.3 TFR2 SLC40A1 HFE HAMP
37 pancytopenia 30.3 THPO IL6 EPO CRP
38 systemic autoimmune disease 30.3 IL6 CRP
39 nutritional deficiency disease 30.3 TMPRSS6 TFRC TF IL6 HJV HAMP
40 essential thrombocythemia 30.3 TNF THPO IL6 EPO CRP
41 placenta disease 30.3 TNF IL6 CRP
42 protein-energy malnutrition 30.3 TNF TF IL6
43 congenital hemolytic anemia 30.3 TF HAMP G6PD EPO
44 paraneoplastic syndromes 30.3 IL6 FGF23
45 neutropenia 30.3 TNF THPO TFRC IL6 EPO CRP
46 liver cirrhosis 30.3 TNF THPO TF IL6 HFE CRP
47 disseminated intravascular coagulation 30.3 TNF MB IL6 CRP
48 osteomyelitis 30.2 TNF IL6 CRP
49 kawasaki disease 30.2 TNF IL6 CRP
50 adult-onset still's disease 30.2 TNF IL6 CRP

Comorbidity relations with Iron Deficiency Anemia via Phenotypic Disease Network (PDN): (show top 50) (show all 96)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Alcoholic Liver Cirrhosis Alzheimer Disease
Anxiety Aortic Valve Disease 1
Ascending Colon Cancer Atrophic Gastritis
Benign Essential Hypertension Bronchitis
Bronchopneumonia Cecal Benign Neoplasm
Celiac Disease 1 Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Intestinal Vascular Insufficiency Chylomicron Retention Disease
Colorectal Cancer Conjunctivitis
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Duodenitis Dysthymic Disorder
Encephalopathy Esophageal Candidiasis
Esophageal Disease Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Folic Acid Deficiency Anemia Gastric Cancer
Gastrointestinal System Cancer Generalized Atherosclerosis
Gout Heart Disease
Hepatic Flexure Cancer Hydronephrosis
Hypersplenism Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Inflammatory Bowel Disease 1 Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Iron Deficiency Anemia:



Diseases related to Iron Deficiency Anemia
Sources

Symptoms & Phenotypes for Iron Deficiency Anemia

About this section

MGI Mouse Phenotypes related to Iron Deficiency Anemia:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 EPO FGF23 FTL G6PD HEPH HFE
2 homeostasis/metabolism MP:0005376 10.38 CRP EPO FGF23 FTL G6PD HEPH
3 cardiovascular system MP:0005385 10.34 CRP EPO FGF23 G6PD HEPH HJV
4 growth/size/body region MP:0005378 10.3 FGF23 FTL G6PD HFE HJV IL6
5 immune system MP:0005387 10.3 CRP EPO FGF23 FTL HEPH HFE
6 digestive/alimentary MP:0005381 10.08 FGF23 HEPH HFE IL6 SLC40A1 TFRC
7 integument MP:0010771 10.06 EPO FGF23 HEPH HJV IL6 SLC11A2
8 liver/biliary system MP:0005370 9.97 EPO FTL HEPH HFE HJV IL6
9 limbs/digits/tail MP:0005371 9.8 EPO FGF23 FTL HFE TF TMPRSS6
10 mortality/aging MP:0010768 9.8 EPO FGF23 FTL G6PD HFE HJV
11 nervous system MP:0003631 9.4 FTL G6PD HEPH HFE HJV IL6
Sources

Drugs & Therapeutics for Iron Deficiency Anemia

About this section

PubMed Health treatment related to Iron Deficiency Anemia: 62

Treatment for iron -deficiency anemia will depend on its cause and severity. Treatments may include dietary changes and supplements, medicines, and surgery . Severe iron -deficiency anemia may require a blood transfusion , iron injections , or intravenous (IV) iron therapy . Treatment may need to be done in a hospital. The goals of treating iron -deficiency anemia are to treat its underlying cause and restore normal levels of red blood cells , hemoglobin , and iron.

Drugs for Iron Deficiency Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clarithromycin Approved Phase 4 81103-11-9 84029
2
Metronidazole Approved Phase 4 443-48-1 4173
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
7
Halofantrine Approved Phase 4 69756-53-2 37393
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Ferrous succinate Approved Phase 4 10030-90-7
10
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
11
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
13
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
17
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
18
Lactoferrin Investigational Phase 4 151186-19-5
19
Cobalamin Experimental Phase 4 13408-78-1 6857388
20 retinol Phase 4
21 Retinol palmitate Phase 4
22 Copper Supplement Phase 4
23 Neurotransmitter Agents Phase 4
24 Citrate Phase 4
25 Anti-Infective Agents Phase 4
26 Vitamin B Complex Phase 4
27 Vitamins Phase 4
28 Vitamin B9 Phase 4
29 Folate Phase 4
30 Vitamin B 12 Phase 4
31 Vitamin B12 Phase 4
32 Ferric Compounds Phase 4
33 Teferrol Phase 4
34 Caseins Phase 4
35 N-Methylaspartate Phase 4
36 Plasma Substitutes Phase 4
37 Blood Substitutes Phase 4
38 Epoetin alfa Phase 4 113427-24-0
39
Ferrous fumarate Approved Phase 3 141-01-5
40 Orange Approved Phase 3
41
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
42
Sorbitol Approved Phase 3 50-70-4 5780
43
Ferric maltol Approved Phase 3 33725-54-1
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
45
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
46
Trichostatin A Experimental Phase 3 58880-19-6
47 Calciferol Phase 3
48 Anticoagulants Phase 3
49 Hibiscus Phase 3
50 Gotu Kola Phase 3

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
2 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
3 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
4 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
5 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
6 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
7 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
8 Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial Unknown status NCT03202615 Phase 4 F (ferrous sulphate)
9 Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability Unknown status NCT03359447 Phase 4 Weekly Ferrous Sulfate;Daily Ferrous Sulfate
10 A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia Completed NCT00802139 Phase 4 venoferrum(iron sucrose);Bolgre (Iron acetyl-transferase)
11 FLIPS: Ferfer Liposomal Iron Performance Study Completed NCT03112187 Phase 4 Iron Supplement
12 Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial Completed NCT00746551 Phase 4 Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
13 Dialysis Patients' Response to IV Iron With Elevated Ferritin Completed NCT00224081 Phase 4 Sodium ferric gluconate,
14 Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial Completed NCT03836703 Phase 4 Feroglobin single daily use;Feroglobin twice daily dose
15 The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children Completed NCT04014855 Phase 4 Iron Supplement
16 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Completed NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
17 Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4 Theragran Hematinic;low molecular weight iron dextran
18 Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy Completed NCT02590224 Phase 4 Ferrous bis-glycinate;Ferrous glycine sulphate
19 Iron Indices and Intravenous Ferumoxytol: Time to Steady State Completed NCT01148745 Phase 4 ferumoxytol
20 Endovenous Versus Liposomal Iron in CKD Completed NCT01864161 Phase 4 gluconate iron;Liposomal iron
21 Use of FERAHEME® (Ferumoxytol) for Severe Chronic Kidney Disease and Peritoneal Dialysis Completed NCT01942460 Phase 4 Ferumoxytol
22 Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for Treatment of IDA in CKD Patients on Hemodialysis Completed NCT01227616 Phase 4 Ferumoxytol;Iron Sucrose
23 A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia. Completed NCT01904864 Phase 4 elemental iron (NovaFerrum®);elemental iron (Ferrous Sulfate)
24 Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy: a Randomised, Comparative, Open-label Trial Completed NCT03188445 Phase 4 Iron Isomaltoside 1000;ferrous fumarate with ascorbic acid
25 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial Completed NCT03438227 Phase 4 Iron dextran;Ferrous sulfate 325mg
26 Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia Completed NCT04267653 Phase 4 Lactoferrin Bovine;Ferrous Sulfate
27 The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA) Completed NCT02631668 Phase 4 ferrous succinate and vitamin C;ferrous succinate;ferrous succinate
28 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
29 Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia Completed NCT03236246 Phase 4 KRX-0502
30 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Completed NCT02905539 Phase 4 Iron Isomaltoside 1000;Ferric Carboxymaltose
31 Comparison of Lactoferrin vs Traditional Iron Therapy for Treatment of Iron Deficiency Anemia in School-age Children. Completed NCT04435574 Phase 4 Lactoferrin;Ferrous Sulfate
32 Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy Recruiting NCT04278651 Phase 4 Ferumoxytol;Ferrous Sulfate
33 Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With Lower Extremity Peripheral Artery Disease Recruiting NCT04083755 Phase 4 Ferric Carboxymaltose Injection [Injectafer]
34 Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (ACCESS): A Double-Dummy Randomized Clinical Trial Recruiting NCT03524651 Phase 4 Ferrous Sulfate;Fe-ASP;Ferrous Sulfate;Fe-ASP
35 The Role Of IV Iron (Ferric Carboxymaltose) And IM Vitamin B12 (Hydroxycobalamin) Supplementation In The Management Of Anaemic Prevalent Indian Hemodialysis Patients: A Parallel Group, Quadruple Blind, Placebo-Controlled, Pragmatic Randomized Control Trial With 2x2 Factorial Design Recruiting NCT04627181 Phase 4 Ferric carboxymaltose;Hydroxycobalamin;Placebo;Placebo
36 the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis Recruiting NCT03748043 Phase 4 Lactoferrin;Ferric Hydroxide Polymaltose
37 A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study Suspended NCT00593619 Phase 4 Iron dextran;Iron sucrose
38 Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin for the Correction of Preoperative Anaemia in Patients Undergoing Orthopaedic Surgery Terminated NCT00706667 Phase 4 Ferinject ®
39 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
40 Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum) Withdrawn NCT01151592 Phase 4 Iron Sucrose
41 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
42 A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) Completed NCT02694978 Phase 3 Ferumoxytol;FCM
43 Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students Completed NCT03940430 Phase 2, Phase 3 Lactoferrin;Ferrous sulfate
44 A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy Completed NCT01425463 Phase 3 Ferrous (II) Glycine Sulphate Complex;Polyferose
45 An Open-label, Randomised Controlled Multi-centre Study to Assess the Impact of Ferric Carboxymaltose in Correcting Iron Deficiency Anaemia Compared With Venofer® (Iron Sucrose) in Chinese Subjects Completed NCT03591406 Phase 3 Ferric carboxymaltose;Iron sucrose
46 Prevalence of Genetic Polymorphisms of DMT1 and Ferroportin Enzymes in Adults With Anemia by Iron Deficiency, and Its Influence on the Efficacy of Conventional and Herbal Treatments Completed NCT01414374 Phase 3 Herbal medicine;Iron
47 Controlled Clinical Trial to Assess the Effect of Multiple Micronutrient Supplementation (Iron, Vitamins A, C, D, Folic Acid and Zinc) on Nutritional and Health Indicators in Infants in Southern Israel. Completed NCT00276198 Phase 3
48 A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia Completed NCT01114217 Phase 3 Ferumoxytol
49 A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia Completed NCT01114204 Phase 3 Ferumoxytol;Iron Sucrose
50 A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia Completed NCT01102413 Phase 3 Monofer;Iron Sulphate

Search NIH Clinical Center for Iron Deficiency Anemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ferric citrate
ferric oxide
ferric oxide yellow
Ferrous fumarate
ferrous gluconate
ferrous sulfate
FERROUS SULFATE GRANULES
FERROUS SULFATE,DRIED
Iron
Iron Carbonyl
iron sucrose
IRON SUMALATE
IRON,PEPTONIZED
Iron-Dextran Complex
Polysaccharide iron complex
Sodium ferric gluconate complex
Sources

Genetic Tests for Iron Deficiency Anemia

About this section

Genetic tests related to Iron Deficiency Anemia:

# Genetic test Affiliating Genes
1 Iron Deficiency Anemia 29
Sources

Anatomical Context for Iron Deficiency Anemia

About this section

MalaCards organs/tissues related to Iron Deficiency Anemia:

40
Kidney, Bone Marrow, Colon, Brain, Small Intestine, Myeloid, Thyroid
Sources

Publications for Iron Deficiency Anemia

About this section

Articles related to Iron Deficiency Anemia:

(show top 50) (show all 7383)
# Title Authors PMID Year
1
Lactoferrin efficacy versus ferrous sulfate in curing iron deficiency and iron deficiency anemia in pregnant women. 61 54
20407805 2010
2
Iron-refractory iron deficiency anemia: new molecular mechanisms. 54 61
19776721 2009
3
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 54 61
20209848 2009
4
Food insecurity is associated with iron deficiency anemia in US adolescents. 54 61
19776137 2009
5
Concomitant severe normocytic and normochromic anemia in poststreptococcal acute glomerulonephritis. 54 61
19915313 2009
6
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms. 61 54
19592582 2009
7
Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients? 61 54
20436728 2009
8
Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. 61 54
19357398 2009
9
Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. 54 61
19639462 2009
10
Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram. 54 61
18776731 2009
11
Nutritional consequences of adjustable gastric banding and gastric bypass: a 1-year prospective study. 54 61
18542847 2009
12
[Density-specific distribution of erythrocytes in different types of anemia]. 54 61
19253711 2009
13
Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. 54 61
19325171 2008
14
Unexplained decline in the prevalence of anemia among US children and women between 1988-1994 and 1999-2002. 54 61
19064522 2008
15
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. 61 54
18603562 2008
16
Weekly training volume and hematological status in female top-level athletes of different sports. 54 61
18974729 2008
17
Serum pro-hepcidin as an indicator of iron status in dialysis patients. 61 54
18503700 2008
18
Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. 61 54
18477354 2008
19
Iron deficiency in young Lebanese children: association with elevated blood lead levels. 54 61
18458574 2008
20
Preventive effect of lactoferrin intake on anemia in female long distance runners. 54 61
18391460 2008
21
Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. 61 54
18446719 2008
22
Iron fortification: its efficacy and safety in relation to infections. 61 54
18297896 2007
23
Features of iron deficiency anemia without increment in soluble transferrin receptor concentration. 61 54
17315212 2007
24
[The expression of TfR1 mRNA and IRP1 mRNA in the placenta from different maternal iron status]. 61 54
17877204 2007
25
[The comparison of diagnostic usefulness of transferrin determination by immunological and chemical method in iron deficiency anemia]. 54 61
17682669 2007
26
Prevalence of iron deficiency and anemia among healthy women of reproductive age in Bhaktapur, Nepal. 54 61
16929243 2007
27
Nonhematological benefits of iron. 54 61
17804903 2007
28
Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. 54 61
17003376 2007
29
[Study on serum erythropoietin levels in patients with hematologic malignancies]. 54 61
17172129 2006
30
Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia? 54 61
17002001 2006
31
The interaction between heart failure and other heart diseases, renal failure, and anemia. 61 54
16949468 2006
32
Gastric antral vascular ectasia (watermelon stomach) in patients with ESRD. 61 54
16731286 2006
33
Iron indices: what do they really mean? 61 54
16830699 2006
34
Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. 54 61
16503547 2006
35
Carbohydrate-deficient isoforms of transferrin (%CDT) and sialic acid (SA) in iron-deficiency anemia. 54 61
16178908 2005
36
Soluble transferrin receptor concentration is not superior to log ferritin for evaluating erythropoiesis in adolescents with iron deficiency anemia. 54 61
15820481 2005
37
Serum transferrin receptor and zinc protoporphyrin as indicators of iron status in African children. 61 54
15755831 2005
38
Soluble transferrin receptor and transferrin receptor-ferritin index in iron deficiency anemia and anemia in rheumatoid arthritis. 61 54
15843240 2005
39
Iron status of the Taiwanese elderly: the prevalence of iron deficiency and elevated iron stores. 61 54
16169840 2005
40
The soluble transferrin receptor (sTfR)-ferritin index is a potential predictor of celiac disease in children with refractory iron deficiency anemia. 61 54
15653440 2005
41
Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients. 61 54
15739025 2005
42
Serum transferrin receptor levels in beta-thalassemia trait. 54 61
15537726 2004
43
Determination of iron absorption from intrinsically labeled microencapsulated ferrous fumarate (sprinkles) in infants with different iron and hematologic status by using a dual-stable-isotope method. 61 54
15531698 2004
44
Recombinant human lactoferrin treatment for global health issues: iron deficiency and acute diarrhea. 54 61
15222487 2004
45
Factors associated with iron deficiency anemia in Brazilian preschool children. 54 61
15192767 2004
46
[Conventional and new laboratory parameters in the evaluation of hematologic disease]. 61 54
15018392 2004
47
Prevalence of iron depletion and anemia in top-level basketball players. 54 61
15129928 2004
48
EPO and TPO sequences do not explain thrombocytosis in iron deficiency anemia. 54 61
14608206 2003
49
Contribution of iron deficiency to anemia in chronic renal failure. 61 54
15025343 2003
50
Lactoferrin sequestration and its contribution to iron-deficiency anemia in Helicobacter pylori-infected gastric mucosa. 54 61
12859729 2003
Sources

Variations for Iron Deficiency Anemia

About this section

ClinVar genetic disease variations for Iron Deficiency Anemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TF NM_001063.4(TF):c.829G>A (p.Gly277Ser) SNV Uncertain significance 12622 rs1799899 3:133475812-133475812 3:133756968-133756968
Sources

Expression for Iron Deficiency Anemia

About this section
Search GEO for disease gene expression data for Iron Deficiency Anemia.
Sources

Pathways for Iron Deficiency Anemia

About this section

Pathways related to Iron Deficiency Anemia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Insulin receptor recycling 65
Show member pathways
 12.29 TFRC TF SLC40A1 SLC11A2 HEPH FTL
2
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.82 TNF THPO IL6 EPO
3
HIF-1 signaling pathway 36
11.77 TFRC TF IL6 EPO
4
Hematopoietic cell lineage 36
11.72 TNF THPO TFRC IL6 EPO
5
HIF-1-alpha transcription factor network 1
11.48 TFRC TF EPO
6
Mineral absorption 36
11.43 TF SLC40A1 SLC11A2 HEPH FTL
7
Differentiation Pathway 1
11.33 TF IL6 EPO
8
Ferroptosis 36
11.17 TFRC TF SLC40A1 SLC11A2 FTL
9
Overview of nanoparticle effects 1
10.86 TNF IL6 CRP
10
Iron metabolism in placenta 1
10.18 TFRC TFR2 TF SLC40A1 SLC11A2 HAMP
11
Hfe effect on hepcidin production 1
10.1 TMPRSS6 HJV HFE HAMP
Sources

GO Terms for Iron Deficiency Anemia

About this section

Cellular components related to Iron Deficiency Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 TNF THPO TFRC TF LTF IL6
2 cell surface GO:0009986 9.88 TNF TFRC TF SLC11A2 LTF EPO
3 early endosome GO:0005769 9.77 TFRC TF SLC11A2 LTF HFE
4 extracellular space GO:0005615 9.77 TNF TMPRSS6 THPO TFRC TF LTF
5 recycling endosome GO:0055037 9.63 TNF TFRC TF SLC11A2 LTF HFE
6 basal part of cell GO:0045178 9.43 TF SLC11A2 HFE
7 HFE-transferrin receptor complex GO:1990712 9.02 TFRC TFR2 TF HJV HFE

Biological processes related to Iron Deficiency Anemia according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.05 TF SLC40A1 SLC11A2 LTF HFE HEPH
2 positive regulation of gene expression GO:0010628 9.95 TNF TFRC IL6 HFE FGF23 CRP
3 cellular protein metabolic process GO:0044267 9.93 TF LTF IL6 FGF23
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 TNF THPO FGF23 EPO
5 positive regulation of protein phosphorylation GO:0001934 9.9 TNF THPO TFRC FGF23
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.87 TNF TFRC LTF IL6
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 TNF TFRC IL6
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 EPO
9 humoral immune response GO:0006959 9.76 TNF LTF IL6
10 acute-phase response GO:0006953 9.73 TFR2 IL6 HFE HAMP EPO CRP
11 iron ion transport GO:0006826 9.7 TFRC TFR2 TF SLC11A2 LTF HEPH
12 iron ion homeostasis GO:0055072 9.7 TMPRSS6 TFR2 TF SLC40A1 SLC11A2 LTF
13 liver regeneration GO:0097421 9.69 IL6 HFE HAMP
14 osteoclast differentiation GO:0030316 9.67 TNF TFRC TF
15 transferrin transport GO:0033572 9.67 TFRC TFR2 TF HFE
16 positive regulation of neuroinflammatory response GO:0150078 9.64 TNF IL6
17 response to salt stress GO:0009651 9.63 TNF EPO
18 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
19 positive regulation of peptide hormone secretion GO:0090277 9.62 TFR2 HFE
20 response to iron ion GO:0010039 9.62 TFR2 SLC11A2 HFE HAMP
21 iron ion transmembrane transport GO:0034755 9.61 SLC40A1 SLC11A2
22 cellular response to iron ion GO:0071281 9.61 TFR2 TF HFE
23 vascular endothelial growth factor production GO:0010573 9.59 TNF IL6
24 multicellular organismal iron ion homeostasis GO:0060586 9.58 SLC40A1 SLC11A2 HAMP
25 divalent inorganic cation transport GO:0072511 9.56 SLC40A1 SLC11A2
26 negative regulation by host of viral process GO:0044793 9.55 LTF CRP
27 response to iron ion starvation GO:1990641 9.54 HFE HAMP
28 regulation of iron ion transport GO:0034756 9.52 TF HFE
29 cellular iron ion homeostasis GO:0006879 9.36 TMPRSS6 TFRC TFR2 TF SLC40A1 SLC11A2

Molecular functions related to Iron Deficiency Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 TNF THPO IL6 EPO
2 ferric iron binding GO:0008199 9.4 TF FTL
3 ferrous iron binding GO:0008198 9.33 TF HEPH FTL
4 iron ion transmembrane transporter activity GO:0005381 9.32 SLC40A1 SLC11A2
5 ferrous iron transmembrane transporter activity GO:0015093 9.26 SLC40A1 SLC11A2
6 transferrin receptor activity GO:0004998 8.96 TFRC TFR2
7 transferrin receptor binding GO:1990459 8.8 TF HJV HFE
Sources

Sources for Iron Deficiency Anemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....